Emiq
Also known as: EMIQ, Isoquercitrin, Enzymatically Modified Isoquercitrin (EMIQ)
Overview
Enzymatically Modified Isoquercitrin (EMIQ) is a modified form of isoquercitrin, a glycoside of the flavonoid quercetin, known for its antioxidant properties and potential cardiovascular benefits. The enzymatic modification enhances its bioavailability, making it more effective than its natural counterpart. EMIQ is primarily sourced from various plants and is used in dietary supplements targeting cardiovascular health. Currently, research on EMIQ is emerging, with moderate evidence from limited randomized controlled trials (RCTs), indicating its effects on improving endothelial function. The product is primarily used in its liquid form and is often combined with other ingredients to improve palatability. As research matures, EMIQ has the potential to be recognized for its health benefits, particularly in individuals at risk for cardiovascular diseases.
Benefits
EMIQ has demonstrated significant potential benefits, particularly in enhancing endothelial function in individuals at risk of cardiovascular disease (CVD). A randomized controlled trial indicated that ingestion of EMIQ resulted in an increase in flow-mediated dilation (FMD) by approximately 1.80% compared to placebo. While no significant effects on blood pressure or cognitive function have been identified, the observed benefits suggest that EMIQ may support cardiovascular health, especially in targeted populations. The evidence supporting these benefits comes from studies that employ rigorous methodologies; however, due to the limited number of human studies, further extensive research is needed to solidify the clinical significance of its effects.
How it works
EMIQ exerts its effects primarily through antioxidant mechanisms and the enhancement of nitric oxide production, which is crucial for vascular relaxation and function. These mechanisms improve endothelial function, thereby benefiting cardiovascular health. EMIQ's enzymatic modification allows for increased bioavailability, leading to higher plasma quercetin metabolites, which may further augment its effects on the cardiovascular system. Although the exact molecular targets remain not fully defined, activation of endothelial nitric oxide synthase (eNOS) could play a significant role.
Side effects
Currently, EMIQ is generally regarded as safe for human consumption, having received approval in Japan as a food additive. However, due to the limited number of human studies conducted, the documented side effects remain scarce. Common and rare side effects have not been extensively reported, and no significant drug interactions with EMIQ have been noted. There are no specific contraindications outlined, though caution is advisable for special populations such as pregnant women or individuals with severe health conditions due to a lack of comprehensive guidance. While EMIQ is considered safe, further studies are warranted to define its safety profile accurately.
Dosage
The minimum effective dose of EMIQ has been suggested at approximately 4.89 mg/kg body weight, translating to an approximate aglycone equivalent of 2 mg. However, optimal dosage ranges have not been established, and the maximum safe dose remains undetermined. Effects are typically observed within hours of ingestion, indicating that timing may be relevant for achieving desired outcomes. For practical usage, EMIQ is usually administered in liquid form, often mixed with other components to enhance taste and palatability, and it presents higher bioavailability than natural isoquercitrin, which should be considered when determining effective dosages.
FAQs
What is EMIQ typically mixed with?
EMIQ is often mixed with other ingredients to improve its taste, making it more palatable for consumers.
Is EMIQ safe for long-term use?
While generally considered safe, more long-term research is needed to confirm its safety profile.
How soon can I expect effects from EMIQ?
Effects on endothelial function can be observed within hours of ingestion.
What results can I expect from taking EMIQ?
Individuals at risk of cardiovascular disease may experience improved endothelial function.
Is EMIQ a cure for cardiovascular diseases?
No, EMIQ is not a cure but may provide supportive cardiovascular benefits.
Research Sources
- https://www.cambridge.org/core/journals/british-journal-of-nutrition/article/enzymatically-modified-isoquercitrin-improves-endothelial-function-in-volunteers-at-risk-of-cardiovascular-disease/E46BB9B730E089DF9458B5A9F18E1974 – This randomized controlled study shows that EMIQ improves endothelial function in individuals at risk of cardiovascular disease (CVD), emphasizing its potential cardiovascular benefits.
- https://journals.plos.org/plosone/article/file?id=10.1371%2Fjournal.pone.0286143&type=printable – The document provides a detailed overview of the characteristics and effects of EMIQ, suggesting that it increases plasma quercetin metabolites, which points to its improved bioavailability.
- https://www.tandfonline.com/doi/full/10.1080/10942912.2022.2127764 – This source reviews the wider implications of polyphenol supplementation, highlighting the need for further targeted research into specific compounds like EMIQ.
- https://core.ac.uk/download/pdf/289100522.pdf – The source offers insights into various studies regarding EMIQ's effects, although specific findings are less detailed.
- https://www.researchgate.net/publication/319453547_Enzymatically_modified_isoquercitrin_supplementation_intensifies_plantaris_muscle_fiber_hypertrophy_in_functionally_overloaded_mice – While primarily focused on EMIQ's effects in animal models, this article indicates potential benefits of EMIQ in muscle hypertrophy, suggesting its varied applications.
